Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging

Steven M Bair; Jakub Svoboda

doi:10.1016/j.cpet.2019.03.008

Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging

PET Clin. 2019 Jul;14(3):353-368. doi: 10.1016/j.cpet.2019.03.008. Epub 2019 Apr 12.

Authors

Steven M Bair¹, Jakub Svoboda²

Affiliations

¹ Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, PCAM 12th Floor, South Extension, Philadelphia, PA 19104, USA. Electronic address: steven.bair@uphs.upenn.edu.
² Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, PCAM 12th Floor, South Extension, Philadelphia, PA 19104, USA.

PMID: 31084775
DOI: 10.1016/j.cpet.2019.03.008

Abstract

Hodgkin lymphoma, a B-cell malignancy, is most common in patients younger than 55 years. Between 70% and 90% are cured with standard approaches. The high cure rate and long-term survival resulted in a need to minimize therapy toxicity. Response-adapted approaches have been developed to de-escalate therapy in those likely to be cured and intensifying therapy in those not responding to initial treatment. FDG-PET after chemotherapy is highly predictive of outcome. Thus, FDG-PET has been incorporated into response-adapted treatments. Use of FDG-PET to guide treatment in Hodgkin lymphoma has been recommended. We summarize literature and discuss challenges and future directions.

Keywords: Hodgkin lymphoma; PET; Prognostic; Response-adapted.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Fluorodeoxyglucose F18*
Hodgkin Disease / diagnostic imaging*
Hodgkin Disease / drug therapy*
Humans
Positron-Emission Tomography / methods*
Radiopharmaceuticals*
Treatment Outcome

Substances

Antineoplastic Agents
Radiopharmaceuticals
Fluorodeoxyglucose F18